Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
17 evidence topics · 17 sources
Fibrosis stage as the primary predictor of outcomes, with higher risk from F2 (at-risk NASH)
“Data from meta-analyses and pooled studies demonstrate that fibrosis and the presence of steatohepatitis are the primary predictors of disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, patients with NASH and at least stage 2 fibrosis (F2), referred to as “at-risk” NASH, have a demonstrably higher risk of liver-related morbidity and mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common causes of death in patients with NAFLD overall are cardiovascular disease (CVD) and nonhepatic malignancy, followed by liver disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bridging fibrosis and cirrhosis are associated with an exponentially greater risk of liver-related morbidity and mortality than earlier stages of fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with cirrhosis, progression to clinical decompensation ranges from 3% to 20% per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
All-cause and liver-related mortality by fibrosis stage: meta-analysis of 14 articles, 17,301 participants with biopsy-proven NAFLD
“Medline and Embase databases were searched to include cohort studies reporting survival outcomes by fibrosis stage in biopsy-proven NAFLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 14 articles involving 17,301 patients with NAFLD were included. All-cause mortality at 1, 5, and 10 years for stage 0 to 2 fibrosis was 0.1%, 3.3%, and 7.7% vs 0.3%, 20.6%, and 41.5% for stage 4 fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with stage 0 fibrosis, all-cause mortality increased with fibrosis stage: stage 2; HR, 1.46 (95% confidence interval [CI], 1.08–1.98), stage 3; HR, 1.96 (95% CI, 1.41–2.72), and stage 4; HR, 3.66 (95% CI, 2.65–5.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Risk for liver-related mortality increased exponentially as fibrosis stage increased: stage 2; HR, 4.07 (95% CI, 1.44–11.5), stage 3; HR, 7.59 (95% CI, 2.80–20.5), and stage 4; HR, 15.1 (95% CI, 5.27–43.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality rate ratios by fibrosis stage: meta-analysis of 5 cohorts, 1,495 participants with NAFLD
“1,495 NAFLD patients with 17,452 patient years of follow-up were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to NAFLD patients with no fibrosis (stage 0), NAFLD patients with fibrosis were at an increased risk for all-cause mortality and this risk increased with increase in the stage of fibrosis: stage 1, MRR, 1.58 (95% CI 1.19–2.11); stage 2, MRR, 2.52 (95% CI 1.85–3.42); stage 3, MRR, 3.48 (95% CI 2.51–4.83), and stage 4, MRR, 6.40 (95% CI 4.11–9.95).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The results were more pronounced as the risk of liver-related mortality increased exponentially with increase in the stage of fibrosis: stage 1, MRR, 1.41 (95% CI 0.17–11.95); stage 2, MRR, 9.57 (95% CI 1.67–54.93); stage 3, MRR, 16.69 (95% CI 2.92–95.36); and stage 4, MRR, 42.30 (95% CI 3.51–510.34).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relative risk of mortality and liver events, stage 4 versus stage 0: meta-analysis of 13 studies, 4,428 participants with NAFLD
“Our meta-analysis included 13 studies, comprising 4428 patients with NAFLD; 2875 of these were reported to have NASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with no fibrosis (stage 0), unadjusted risk increased with increasing stage of fibrosis (stage 0 vs 4): all-cause mortality RR, 3.42 (95% CI, 2.63-4.46); liver-related mortality RR, 11.13 (95% CI, 4.15-29.84); liver transplant RR, 5.42 (95% CI, 1.05-27.89); and liver-related events RR, 12.78 (95% CI, 6.85-23.85).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Death or liver transplantation and liver-related events by fibrosis stage: 619 participants with biopsy-diagnosed NAFLD, median 12.6 years
“We performed a retrospective analysis of 619 patients diagnosed with NAFLD from 1975 through 2005 at medical centers in the United States, Europe, and Thailand.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over a median follow-up of 12.6 years (range 0.3–35.1), 193 of the patients (33.2%) died or underwent liver transplantation. Features of liver biopsies significantly associated with death or liver transplantation included fibrosis stage 1 (HR, 1.88; 95% CI, 1.28, 2.77), stage 2 (HR, 2.89; 95% CI, 1.93, 4.33), stage 3 (HR, 3.76; 95% CI, 2.40, 5.89), and stage 4 (HR, 10.9; 95% CI, 6.06, 19.62) compared with stage 0” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-six patients (4.2%) developed liver-related events; fibrosis stage 3 (HR 14.2 [95% CI 3.38, 59.68]) and stage 4 (HR 51.5 [95% CI 9.87, 269.2]) compared to stage 0, were significantly associated with the events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths and liver-related complications per 100 person-years by fibrosis stage: prospective NASH CRN cohort, 1,773 adults, median 4 years
“A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality by histologic stage versus matched controls: Swedish nationwide biopsy cohort, 10,568 participants, median 14.2 years
“This nationwide, matched cohort study included all individuals in Sweden with biopsy-confirmed NAFLD (1966–2017; n=10,568).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over a median of 14.2 years, 4,338 NAFLD patients died.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to controls, significant excess mortality risk was observed with simple steatosis (8.3/1000PY, aHR=1.71, 95%CI=1.64–1.79), non-fibrotic NASH (13.4/1000PY, aHR=2.14, 95%CI=1.93–2.38), non-cirrhotic fibrosis (18.4/1000PY, aHR=2.44, 95%CI=2.22–2.69) and cirrhosis (53.6/1000PY, aHR=3.79, 95%CI=3.34–4.30)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The excess mortality associated with NAFLD was primarily from extra-hepatic cancer (4.5/1000PY; aHR=2.16, 95%CI=2.03–2.30), followed by cirrhosis (2.7/1000PY; aHR=18.15, 95%CI=14.78–22.30), cardiovascular disease (1.4/1000PY; aHR=1.35, 95%CI=1.26–1.44) and hepatocellular carcinoma (HCC)(1.2/1000PY; aHR=11.12, 95%CI=8.65–14.30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Major adverse liver outcomes by fibrosis stage: Swedish cohort of 1,260 participants with non-cirrhotic NAFLD, median 13 years
“Patients (n = 1,260) with NAFLD without cirrhosis were diagnosed through biopsy or radiology, and had fibrosis estimated through vibration-controlled transient elastography, biopsy, or FIB-4 score between 1974 and 2020 and followed up through 2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MALO occurred in 111 (8.8%, incidence rate = 5.9/1,000 person-years) patients with NAFLD and 197 (1.6%, incidence rate = 1.0/1,000 person-years) reference individuals during a median follow up of 13 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 20-year cumulative incidences of MALO were 2% for the reference population, 3% for patients with F0, and 35% for F3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The adjusted hazard ratio (aHR) for F2, as determined by biopsy, was 2.9 (95% CI 1.5–5.5), and for F3 the aHR was 8.9 (95% CI 4.6–17.4), both compared with the reference group with F0–1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression to cirrhosis and all-cause mortality in non-cirrhotic MASH F2 and F3: US TARGET-NASH cohort, 2,378 participants
“Among the 2378 patients included in this analysis, 48% had MASH cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 1425 patients with non-cirrhotic MASH, there were 982 patients in the F0–F1 cohort, 281 patients in the F2 cohort, and 162 patients in the F3 cohort (Supplemental Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence rates of cirrhosis increased from 0.34/100PM in the F0–F1 cohort to 1.24/100PM in the F2 cohort and 6.62/100PM in the F3 cohort (Table 5). Unadjusted risk of progressing to cirrhosis was highest among those with F3 (HR, 95% CI; 18.66, 10.97–31.73) and 3.74 times higher with F2 (HR, 95% CI; 3.74, 2.00–6.98) versus F0–F1 (Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause mortality was associated with disease severity and incidence rates increased from 0.14/100PM in the F0–F1 cohort to 0.3/100PM in the F2 cohort, 0.42/100PM in the F3 cohort, 2.02/100PM in the compensated cirrhosis cohort and 4.62/100PM in the decompensated cirrhosis cohort (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis was supported by Novo Nordisk Inc., Plainsboro, NJ.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis progression and regression rates and times by stage: meta-analysis of 54 paired biopsy or imaging studies
“Time to progress by 1 fibrosis stage was 9.9, 10.3, 13.3 and 22.2 years for F0, F1, F2, and F3, respectively. Time to regress by 1 stage was 21.3, 12.5, 20.4, and 40.0 years for F4, F3, F2, and F1, respectively. Rates estimated from RCTs were higher than those from observational studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with F2, a similar proportion progressed, regressed, or remained stable (32%, 37%, and 31%, respectively) after 5 years. Patients with F3 regressed more often than progressed, 32% vs. 22%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled incidence of progression from F0, F1, F2, and F3 were 6.5, 6.9, 5.8, and 4.5/100 person-years, respectively (Table 3). Pooled incidence for regression from F1, F2, F3, and F4 were 2.5, 4.6, 6.0, and 4.7/100 person-years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis progression rate in NASH versus NAFL: meta-analysis of 11 paired biopsy cohorts, 411 participants
“We identified 11 cohort studies including 411 patients with biopsy-proven NAFLD (150 with NAFL and 261 with NASH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over 2145.5 person-years of follow up, 33.6% had fibrosis progression, 43.1% had stable fibrosis, and 22.3% had improvement in fibrosis stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings correspond to 1 stage of progression over14.3 years for patients with NAFL (95% CI, 9.1–50.0 years) and 7.1 years for patients with NASH (95% CI, 4.8–14.3 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis progression in NASH and mortality rates in NAFLD and NASH: global meta-analysis
“Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
All-cause and cause-specific mortality among adults with NAFLD: global meta-analysis
“Among the NAFLD population, the pooled mortality rate (n=3) in studies that had used ultrasound or serum diagnostic method was 12.60 per 1000 PY (6.68–23.67) for all-cause mortality; 4.20 per 1000 PY (1.34–7.05) for cardiac-specific mortality; 2.83 per 1000 PY (0.78–4.88) for extrahepatic cancer-specific mortality; and 0.92 per 1000 PY (0.00–2.21) for liver-specific mortality (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression from steatosis to steatohepatitis, effect of type 2 diabetes, and cause-specific mortality by histologic stage
US NAFLD-related decompensated cirrhosis, hepatocellular carcinoma, and liver deaths, projected 2015 to 2030, Markov model
“Incident decompensated cirrhosis is forecasted to increase by 168%, from 39,320 cases annually in 2015 to 105,430 cases in 2030” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“incident HCC cases are expected to increase by 137% from 5,160 to 12,240 in 2030 (Fig. 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Liver deaths are projected at 78,300 in 2030, an increase of 178% from 2015 (Fig. 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote